Condition evidence map
Heart failure with preserved ejection fraction (HFpEF)
Research evidence map for HFpEF in adults with obesity: SUMMIT trial of tirzepatide and the Kansas City Cardiomyopathy Questionnaire endpoint.
Research context
HFpEF — heart failure with an ejection fraction of 50% or above — has historically had few effective pharmacotherapies. SUMMIT enrolled adults with HFpEF and obesity (BMI ≥30) and reported that tirzepatide reduced the composite of CV death or worsening heart-failure events versus placebo while improving the KCCQ-CSS quality-of-life score.
Why this matters metabolically
HFpEF in adults with obesity is one of the clearest examples of metabolic disease driving cardiac disease. Targeting obesity pharmacologically appears to reach the underlying physiology.
FAQs
- Is tirzepatide licensed for HFpEF in the UK?
- Not as a stand-alone indication at the time of review. SUMMIT informs clinical practice for adults with HFpEF and obesity but UK access is via the licensed obesity / T2D indications.
- SUMMIT does not establish benefit in HFpEF without coexisting obesity.
- SUMMIT does not establish benefit in HFrEF (heart failure with reduced ejection fraction).
- A 52-week trial does not characterise long-term heart-failure trajectory.
Related mechanisms
Related peptide profiles
Related trials
Related safety signals
Related conditions
Sources are tagged by class. Regulatory documents, peer-reviewed publications and trial registry records are preferred. Manufacturer disclosures and conference material are accepted where peer-reviewed publication is not yet available; preprints are flagged.
- Trial registry recordSUMMIT — tirzepatide in heart failure with preserved ejection fraction and obesity (ClinicalTrials.gov NCT04847557).
- Regulatory document (MHRA/EMA/FDA)MHRA — Medicines and Healthcare products Regulatory Agency
UK regulatory authority for medicines and medical devices
- Regulatory document (MHRA/EMA/FDA)NICE — National Institute for Health and Care Excellence
NICE guidance on treatment pathways for metabolic conditions
- Editorial synthesisSite editorial synthesis — Metabolic Peptides
Editorial summary of condition profiles on this site